Europe Human Microbiome Market

The report "Europe Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics, Synbiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031" is projected to grow from USD 0.29 billion in 2025 and to reach USD 1.31 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 28.6% during the forecast period.

Browse 250 market data Tables and 50 Figures spread through 414 Pages and in-depth TOC on "Europe Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics, Synbiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031"

View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/europe-human-microbiome-market-66008771.html

The Europe human microbiome market is expected to reach USD 1.31 billion by 2031, up from USD 0.29 billion in 2025, with a CAGR of 28.6% over the forecast period.

The increasing emphasis on probiotics has been acting as a significant growth factor in the Europe Human Microbiome Market. These metabolites and cellular components from probiotics are emerging for their health benefits and wide range of applications. Advancements in postbiotic research are opening the way for microbiome therapeutics and consumer health products, thereby driving R&D, collaborations, and commercialization across Europe. This trend is influencing the shift toward microbiome-based interventions, as well as the development of future healthcare systems. Nevertheless, the presence of various and changing regulatory frameworks in European countries may create difficulties in product approval and market expansion, despite increased adoption and consumer interest.

By type, the live bacteria products segment accounted for the largest share of the market in 2024.

The Europe human microbiome market by type is categorized into bacterial consortia transplantation (BCT)/fecal microbiota transplantation (FMT), live bacteria products, and other products. Bacterial consortia transplantation (BCT)/fecal microbiota transplantation (FMT) and live bacteria products, and other products. In 2024, the largest share of the Europe human microbiome market was held by live bacteria products. This involves probiotics and synbiotics that are commonly used in both supplements and newly developed therapeutics. The expansion is a result of the increased consumer focus on gut health, the immune system, and general well-being, which is also strongly supported by clinical trials of specific strains. Across Europe, well-established distribution networks, mature supplement markets, and more straightforward regulatory pathways facilitate commercialization. The developments in encapsulation, targeted delivery, and strain-specific formulations enhance efficiency and facilitate preventive, personalized, and condition-specific usage.

By end user, the hospitals & clinics segment accounted for the largest share of the market in 2024.

The Europe human microbiome market is divided according to the end users into hospitals & clinics, long-term care facilities, and other end users. In 2024, hospitals and clinics are expected to contribute the largest share of the market. Their dominant position in this section stems from their role as the primary players in the delivery and regulation of microbiome therapies for gastrointestinal, metabolic, and infectious diseases. To ensure safety and adherence to rules, approved therapies, including FMT products, are primarily administered in clinical settings. In addition, hospitals gather the resources for storage, cold-chain logistics, and patient follow-up, and also serve as centres for clinical trials and real-world studies. The increase in chronic and microbiome-related diseases, the presence of well-trained professionals, and the availability of advanced diagnostic tools are some of the factors that will drive further adoption of microbiome therapy across Europe.

By country, the UK accounted for the largest share of the market in 2024.

Among the human microbiome markets in Europe, the UK was the largest market in 2024. One of the primary reasons for this is a vibrant biotech ecosystem complemented by a robust research infrastructure. With regulatory programs, such as approvals for therapeutics that treat recurrent Clostridioides difficile and other microbiome-related conditions, there has been a surge in investment in pharmaceuticals, consumer health products, and new therapeutics. The sale of probiotics, prebiotics, and synbiotics has mostly since people have become more aware of gut health, immunity, and preventive wellness. The UK is the leading market in Europe, mainly due to its large number of clinical trials supported by academic research, high healthcare spending, and innovative funding.

Some of the leading players in the market include Ferring B.V. (Switzerland), OptiBiotix Health PLC (UK), BioGaia (Sweden), MaaT Pharma (France), Actial Farmaceutica srl (Italy), and nfant Bacterial Therapeutics AB. (Sweden), OxThera (Sweden), and Nexbiome (France), among others.

Don’t miss out on business opportunities in Europe Human Microbiome Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/